<DOC>
	<DOCNO>NCT00651144</DOCNO>
	<brief_summary>The purpose study obtain data coadministration ezetimibe rosuvastatin support concomitant use two drug patient require additional cholesterol-lowering management . Treatment administer 14 day .</brief_summary>
	<brief_title>Assessment Potential Interaction Between Ezetimibe Rosuvastatin Healthy Subjects With High Cholesterol ( P03317 )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Males female age 18 55 year inclusive , Body Mass Index ( BMI ) 1931 inclusive . BMI=weight ( kg ) /height ( m^2 ) . Subjects must untreated hypercholesterolemia directly measure fast LDLC &gt; =130 mg/dL ( 3.37 mmol/L ) Screening Day 1 . Subjects must free clinically significant disease require physician 's care and/or would interfere study evaluation . Subjects must normal clinically acceptable physical exam ECG ( 12lead record 25 mm/s report heart rate PR , QRS , QT , QTc interval ) . Subjects ' clinical laboratory test ( CBC , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator/ sponsor . Screen drug high potential abuse must negative . Subjects must willing give write informed consent able adhere dose visit schedule . Subjects must willing comply NCEP Step 1 diet least one week outpatient , inpatient treatment period . Female subject must nonchildbearing potential ( ie , surgically sterilize postmenopausal least one year ) , , childbearing potential must use medically accept method birth control prior Screening agree continue use study surgically sterilize ( eg , hysterectomy tubal ligation ) . Females childbearing potential counseled appropriate use birth control study . Females currently sexually active must agree consent use one abovementioned method become sexually active participate study . Female subject must negative serum pregnancy test ( betahCG ) Screening . Female subject pregnant , intend become pregnant , nursing . Subjects previously receive treated ezetimibe ( SCH 58235 ) rosuvastatin . Subjects previously receive treated lipid lower drug ( include OTC fish oil phytosterols ) within 6 week Visit 1 . Any subject comply requirement he/she use prescription overthecounter drug ( except aspirin acetaminophen [ paracetamol ] ) within two week prior study drug administration alcohol within 48 hour prior study drug administration . Subjects use investigational drug donate blood within 30 day study entry . Subjects preexist gallbladder disease history liver function test abnormality . Subjects smoke ten cigarette equivalent tobacco use per day . Subjects clinically significant allergy intolerance food drug , especially component ezetimibe ( ZETIA™/EZETROL™ ) rosuvastatin ( CRESTOR™ ) . Subjects positive HIV antibody , hepatitis B surface antigen hepatitis C antibody . Subjects history mental instability treat mood disorder . Subjects situation condition , opinion investigator , may interfere optimal participation study . Subjects participate clinical study . Subjects part staff personnel directly involve study . Subjects family member investigational study staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>